Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,849 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: First Treatment Period Clear all
Active, not recruiting Phase 4 Interventional

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

NCT05003648
View directory record Official record
Conditions
Adrenoleukodystrophy, Restless Legs Syndrome
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 12, 2026, 10:36 PM EDT
Active, not recruiting Not applicable Interventional

SMART Stepped Care Management for Low Back Pain in the Military Health System

NCT04172038
View directory record Official record
Conditions
Low Back Pain, Chronic Pain, Military Personnel, Veterans
Interventions
Physical Therapy, Move 2 Health (M2H), MORE Mindfulness
Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
Schofield Barracks, Hawaii • San Antonio, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 12, 2026, 10:36 PM EDT
Active, not recruiting Phase 1 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions
Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

NCT03724747
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
BAY2315497 Injection, Darolutamide(BAY1841788)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
New Orleans, Louisiana • Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

NCT01714726
View directory record Official record
Conditions
Crohn's Disease
Interventions
MEDI2070, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
26
States / cities
Encinitas, California • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 12, 2026, 10:36 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors

NCT04299191
View directory record Official record
Conditions
High-grade Glioma, Solid Tumor, Unspecified, Child
Interventions
LAM561
Drug
Lead sponsor
Laminar Pharmaceuticals
Industry
Eligibility
Up to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Little Rock, Arkansas • Miami, Florida • Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

NCT01555125
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
secukinumab 150 mg, secukinumab 300 mg, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis

NCT03390491
View directory record Official record
Conditions
Psychosis, Schizoaffective Disorder, Schizophrenia
Interventions
OnTrack>TheGame (OTG), Recovery Videos (RV)
Behavioral
Lead sponsor
Center for Social Innovation, Massachusetts
Other
Eligibility
16 Years to 30 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 12, 2026, 10:36 PM EDT
Terminated Phase 3 Interventional Results available

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

NCT04963270
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Satralizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • Pasadena, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 12, 2026, 10:36 PM EDT
Terminated Not applicable Interventional Results available

Brain Stimulation and Rehabilitation for Adults With Chronic, Severe Arm Motor Impairment After Stroke

NCT03538795
View directory record Official record
Conditions
Stroke, Hemiplegia, Hemiparesis
Interventions
iTBS&eCIMT
Combination Product
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 12, 2026, 10:36 PM EDT
Recruiting Not applicable Interventional

The Effect of Manual Physical Therapy and Exercise in Addition to Routine Dental Care in Individuals With Temporomandibular Disorders

NCT06602375
View directory record Official record
Conditions
Temporomandibular Disorders (TMD)
Interventions
Standard care, Physical Therapy (PT)
Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 12, 2026, 10:36 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

NCT00401401
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Cancer
Interventions
zalutumumab, cisplatin, Radiotherapy
Drug · Procedure
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 22, 2011 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Results available

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03227445
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ELLIPTA placebo DPI, DISKUS placebo DPI, HandiHaler placebo DPI, Inhaler preference questionnaires
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Orlando, Florida • Natchitoches, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

NCT01164475
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Granulocyte-colony stimulating factor (G-CSF), Fixed Dose Plerixafor, Weight-Based Plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 78 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Duarte, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Pelvic Floor Muscle Training With a Digital Therapeutic Device to Standard Exercises for Stress Urinary Incontinence

NCT04508153
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Leva Pelvic Digital Health System, Kegel exercises
Device · Other
Lead sponsor
Renovia, Inc.
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Birmingham, Alabama • Irvine, California • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 12, 2026, 10:36 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Caring for Caregivers of Individuals With Alzheimer's Disease

NCT07486037
View directory record Official record
Conditions
Intervention Group, Treatment as Usual
Interventions
Exercise
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer

NCT02775695
View directory record Official record
Conditions
Resectable Pancreatic Cancer
Interventions
Doxycycline
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 12, 2026, 10:36 PM EDT
Withdrawn Phase 2 Interventional

A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients

NCT02857244
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Duloxetine, Donepezil, Modafinil
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Mitochondria and Chronic Kidney Disease

NCT03177798
View directory record Official record
Conditions
Hemodialysis-Induced Symptom, Mitochondrial Diseases
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 78 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 12, 2026, 10:36 PM EDT
Terminated Not applicable Interventional Results available

Temperature Manipulating Gloves for the Treatment of Insomnia

NCT02341287
View directory record Official record
Conditions
Insomnia
Interventions
Warming hydrogel glove, Non-thermal glove
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Reducing Fetal Exposure to Maternal Depression to Improve Infant Risk Mechanisms

NCT03011801
View directory record Official record
Conditions
Depression
Interventions
Interpersonal Therapy, Enhanced usual care
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older · Female only
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 12, 2026, 10:36 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

NCT03656536
View directory record Official record
Conditions
Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma
Interventions
Pemigatinib, Gemcitabine, Cisplatin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
36
States / cities
Phoenix, Arizona • Greenbrae, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Open Label Placebo in Children With FGIDs

NCT02389998
View directory record Official record
Conditions
Functional Abdominal Pain, Functional Dyspepsia, Irritable Bowel Syndrome, Functional Gastrointestinal Disorders
Interventions
Placebo Suspension, Hyoscyamine
Other · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

NCT02292784
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban, Atosiban, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Weeks to 20 Weeks
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Park Ridge, Illinois • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 12, 2026, 10:36 PM EDT